First 100 Patients Treated in Europe with the MitraClip(R) System for Percutaneous Mitral Repair
Use of the MitraClip(R) Therapy Continues to Expand in
MR is the most common type of heart valve insufficiency in
“We have seen that the MitraClip(R) therapy provides a valuable alternative for patients who are considered high risk or otherwise not good candidates for surgery,” said
“The MitraClip(R) therapy has not only played a key role for patients considered too high-risk for surgery, but has also been shown to be effective in selected surgical candidates,” added
As of today, patients have been treated with the MitraClip(R) system at fourteen institutions throughout
“The successful treatment of the 100th patient in
Evalve initiated commercial sales of the MitraClip(R) system in
About the MitraClip(R) Procedure
Percutaneous mitral repair with Evalve’s MitraClip(R) device is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.
About Evalve, Inc.
Founded in 1999, Evalve, Inc., headquartered in
The MitraClip(R) system is currently undergoing clinical evaluation in
MitraClip(R) and Evalve(R) are registered trademarks of Evalve, Inc.
Media Contact: Lisa Waters Edelman 1-323-202-1051 Lisa.Waters@edelman.com
SOURCE Evalve, Inc.